Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis

Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis

AbstractBackground Some patients with severe asthma may benefit from treatment with biologics, but evidence has been mostly collected from randomized controlled trials (RCTs), in which patients’ characteristics are different from those encountered in asthma patients in the real-world setting. The ai...

Full description

Bibliographic Details
Main Authors:	Maria Basagaña, Carlos Martínez-Rivera, Clara Padró, Ignasi Garcia-Olivé, Mimar Martínez-Colls, Juan Navarro, Laura Pardo, Paula Cruz, Gloria Cardona Peitx, Lídia Carabias, Albert Roger, Jorge Abad, Antoni Rosell
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Annals of Medicine
Subjects:	Severe asthma biologics omalizumab benralizumab mepolizumab retrospective analysis
Online Access:	https://www.tandfonline.com/doi/10.1080/07853890.2024.2317356

Similar Items

Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
by: Alistair Cook, et al.
Published: (2021-05-01)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
by: Erminia Ridolo, et al.
Published: (2020-10-01)

Characterization of Severe Uncontrolled Asthma in Japan: Analysis of Baseline Data from the PROSPECT Study
by: Koya T, et al.
Published: (2023-06-01)

Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study
by: Numata T, et al.
Published: (2021-06-01)

Efficacy of tezepelumab against uncontrolled severe non‐type 2 asthma refractory to bronchial thermoplasty, benralizumab, dupilumab and mepolizumab
by: Yoshiro Kai, et al.
Published: (2024-03-01)

Combining Biologics Targeting Eosinophils (IL-5/IL-5R), IgE, and IL-4/IL-13 in Allergic and Inflammatory Diseases
by: Mitchell M. Pitlick, MD, et al.
Published: (2022-11-01)

Anaphylaxis to three humanized antibodies for severe asthma: a case study
by: Koichi Jingo, et al.
Published: (2020-06-01)

Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction [Corrigendum]
by: Ramphul M, et al.
Published: (2021-07-01)

Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction
by: Ramphul M, et al.
Published: (2021-05-01)

Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment
by: Lorenza Vantaggiato, et al.
Published: (2022-03-01)

Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
by: Mattia Giovannini, et al.
Published: (2019-11-01)

Effects of Therapeutic Antibodies on Gene and Protein Signatures in Asthma Patients: A Comparative Systematic Review
by: Maria J. Martin, et al.
Published: (2022-01-01)

Elaborate biologic approval process delays care of patients with moderate-to-severe asthma
by: Esha Sehanobish, PhD, et al.
Published: (2023-05-01)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
by: Arian Ghassemian, et al.
Published: (2021-01-01)

Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty
by: Menzella F, et al.
Published: (2017-11-01)

Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy
by: Corrado Pelaia, et al.
Published: (2021-12-01)

Initiation, response assessment, and switch of antibody therapies in patients with severe asthma – A survey among German specialists
by: Hendrik Suhling, MD, et al.
Published: (2023-12-01)

Unanswered questions on the use of biologics in pediatric asthma
by: Antonio Nieto, MD, PhD, et al.
Published: (2023-11-01)

Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma
by: S. K. Zyryanov, et al.
Published: (2020-12-01)

Switching from omalizumab to mepolizumab therapy improved extra‐pulmonary abdominal and cutaneous vasculitis symptoms in a patient with eosinophilic granulomatosis with polyangiitis
by: Yu‐Hsuan Chen, et al.
Published: (2022-01-01)

Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein–protein interaction analyses
by: Ayobami Akenroye, et al.
Published: (2023-12-01)

Successful simultaneous targeting of IgE and IL-5 in a severe asthmatic patient selected for lung transplantation
by: Karl-Christian Bergmann, PhD, MD, et al.
Published: (2022-08-01)

Monoclonal antibodies targeting small airways: a new perspective for biological therapies in severe asthma
by: Carlo Lombardi, et al.
Published: (2022-10-01)

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma
by: Manuel David Gil-Sierra, et al.
Published: (2019-11-01)

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
by: Carlos Martínez-Rivera, et al.
Published: (2021-01-01)

Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series
by: Pelletier G, et al.
Published: (2022-05-01)

Eosinophilic granulomatosis with polyangiitis developed during treatment with benralizmab for severe asthma: A case report and literature review
by: Mitsukuni Sakabe, et al.
Published: (2024-07-01)

Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab
by: Carpagnano GE, et al.
Published: (2019-03-01)

Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma
by: Drick N, et al.
Published: (2020-11-01)

Effect of the SARS-CoV-2 pandemic on treatment processes of patients with severe asthma who were managed with monoclonal antibody
by: Emel Atayık, et al.
Published: (2022-10-01)

Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome
by: Poddighe D, et al.
Published: (2021-12-01)

Safety and efficacy of monoclonal antibodies targeting IL-5 in severe eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials
by: Noor Alam, et al.
Published: (2023-09-01)

Efficacy and safety of anti-interleukin-5 therapy in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized, controlled trials
by: Shao-Huan Lan, et al.
Published: (2022-02-01)

Factors influencing poor response to type 2 targeted therapies in severe asthma: a retrospective cohort study
by: Mona Al-Ahmad, et al.
Published: (2023-12-01)

Elevated mepolizumab levels in patients with severe asthma responsive to 1 year’s mepolizumab treatment
by: Takayasu Nishimaki, MD, et al.
Published: (2025-05-01)

Complete relief by omalizumab in eruptive pruritic papular porokeratosis
by: Hongxia Jia, MM, et al.
Published: (2024-07-01)

Biological therapy in severe asthma: A gem or a jam
by: Hesham Raafat
Published: (2016-02-01)

Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach
by: Marco Caminati, MD, et al.
Published: (2024-08-01)

Insight into IL-5 as a Potential Target for the Treatment of Allergic Diseases
by: Katarzyna Antosz, et al.
Published: (2024-07-01)

Exploring the risk of infection events in patients with asthma receiving anti-IL-5 monoclonal antibodies: A rapid systematic review and a meta-analysis
by: Riccardo Giossi, et al.
Published: (2024-01-01)